Advertisement
Screener

Seaport Therapeutics, Inc. (SPTX) Graph

SPTX Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $24.62M; Operating expenses $65.81M; Income tax $251.00K; Net income -$62.60M.
  • 2026-03-31: Research and development $21.43M; Operating expenses $27.54M; Income tax $519.00K; Net income -$25.41M.
  • 2025-06-30: Research and development $13.41M; Operating expenses $18.47M; Income tax $134.00K; Net income -$15.08M.
  • 2025-03-31: Research and development $10.53M; Operating expenses $16.18M; Income tax $31.00K; Net income -$13.13M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$24.62M$65.81M$251.00K-$62.60M
2026-03-31$21.43M$27.54M$519.00K-$25.41M
2025-06-30$13.41M$18.47M$134.00K-$15.08M
2025-03-31$10.53M$16.18M$31.00K-$13.13M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$46.05M$93.35M$770.00K-$88.01M
2025-06-30$23.94M$34.66M$165.00K-$28.20M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Amphastar Pharmaceuticals, Inc. (AMPH)United States$1.116B10.93
Latigo Biotherapeutics, Inc. (LTGO)United States$1.176B
Jaguar Health, Inc. (JAGX)United States$1.184B
Alto Neuroscience, Inc. (ANRO)United States$1.065B-11.02
MANNKIND CORP (MNKD)United States$1.058B-30.41
Savara Inc (SVRA)United States$1.044B-9.10
LB PHARMACEUTICALS INC (LBRX)United States$1.220B-10.87
OPKO HEALTH, INC. (OPK)United States$1.220B-15.59
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
HARROW, INC. (HROW)United States$1.240B-42.77